Amneal Pharmaceuticals (NASDAQ:AMRX) gained FDA clearance for new iohexol injection strengths and vial sizes and plans a U.S. hospital/imaging center rollout in Q3 2026, prompting UBS to keep a Buy and raise its price target to $23 from $19.
Previous Week Recap
- Amrx FDA Approval For Iohexol Injection: AMRX won FDA approval for new iohexol injection strengths/vial sizes (350 mg/mL: 50/75/100 mL; 300 mg/mL: 50 mL). Company plans U.S. hospital/imaging center launch in Q3 2026.
- UBS Raises Amneal Target To $23: UBS kept a Buy on Amneal Pharmaceuticals (AMRX) and raised its price target to $23 from $19, a $4 upward revision to the target while maintaining the Buy rating.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.